MRI‐based radiomic features for identifying recurrent prostate cancer after proton radiation therapy
Purpose Magnetic Resonance Imaging (MRI) evaluation of recurrent prostate cancer (PCa) following proton beam therapy is challenging due to radiation‐induced tissue changes. This study aimed to evaluate MRI‐based radiomic features so as to identify the recurrent PCa after proton therapy. Methods We r...
Gespeichert in:
Veröffentlicht in: | Journal of Applied Clinical Medical Physics 2024-03, Vol.25 (3), p.e14293-n/a |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | n/a |
---|---|
container_issue | 3 |
container_start_page | e14293 |
container_title | Journal of Applied Clinical Medical Physics |
container_volume | 25 |
creator | Gumus, Kazim Z. Contreras, Samuel Serrano Al‐Toubat, Mohammed Harmon, Ira Hernandez, Mauricio Ozdemir, Savas Kumar, Sindhu Yuruk, Nurcan Mete, Mutlu Balaji, K. C. Bandyk, Mark Gopireddy, Dheeraj R. |
description | Purpose
Magnetic Resonance Imaging (MRI) evaluation of recurrent prostate cancer (PCa) following proton beam therapy is challenging due to radiation‐induced tissue changes. This study aimed to evaluate MRI‐based radiomic features so as to identify the recurrent PCa after proton therapy.
Methods
We retrospectively studied 12 patients with biochemical recurrence (BCR) following proton therapy. Two experienced radiologists identified prostate lesions from multi‐parametric MRI (mpMRI) images post‐proton therapy and marked control regions of interest (ROIs) on the contralateral side of the prostate gland. A total of 210 radiomic features were extracted from lesions and control regions on the T2‐weighted (T2WI) and Apparent Diffusion Coefficient (ADC) image series. Recursive Feature Elimination with Cross‐Validation method (RFE‐CV) was used for feature selection. A Multilayer Perceptron (MLP) neural network was developed to classify three classes: cancerous, benign, and healthy tissue. The 12‐core biopsy results were used as the gold standard for the segmentations. The classifier performance was measured using specificity, sensitivity, the area under receiver operating characteristic curve (AUC), and other statistical indicators.
Results
Based on biopsy results, 10 lesions were identified as PCa recurrence while eight lesions were confirmed to be benign. Ten radiomic features (10/210) were selected to build the multi‐class classifier. The radiomics classifier gave an accuracy of 0.83 in identifying cancerous, benign, and healthy tissue with a sensitivity of 0.80 and specificity of 0.85. The model yielded an AUC of 0.87, 95% CI [0.72–1.00] in differentiating cancer from the benign and healthy tissues.
Conclusions
Our proof‐of‐concept study demonstrates the potential of using radiomic features as part of the differential diagnosis of PCa on mpMRI following proton therapy. The results need to be validated in a larger cohort. |
doi_str_mv | 10.1002/acm2.14293 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10930012</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A796754946</galeid><sourcerecordid>A796754946</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5163-58effabe1de6e5dd94ef30e7a7d43e834b68f7a52e113757aa698a956774b0593</originalsourceid><addsrcrecordid>eNp9kd1qFDEUxwdRbK3e-AAy4I0Iu-ZzMrmSZfGj0CKIXoczmZNtyuxkzcxU9s5H6DP2STzbqaV6IYHk5OSX__kqipecLTlj4h34rVhyJax8VBxzLaqFtVw9fmAfFc-G4ZIxzmtZPy2OZK2YtcocF-H86-nNr-sGBmzLDG1M2-jLgDBOGYcypFzGFvsxhn3sN2VGP-VM93KX0zDCiKWH3mMuIYy0k3dM_a0QjJGs8QIz7PbPiycBugFf3J0nxfePH76tPy_Ovnw6Xa_OFl7zSi50jSFAg7zFCnXbWoVBMjRgWiWxlqqp6mBAC-RcGm0AKluD1ZUxqmHaypPi_ay7m5ottp4yzdC5XY5byHuXILq_X_p44TbpynFmJfVHkMKbO4Wcfkw4jG4bB49dBz2maXDUZaGkFLoi9PU_6GWack_1EaW1FJWUmqjlTG2gQxf7kCiwp9UitTr1GCL5V8ZWRiurDrJv5w-eWjxkDPfpc-YOA3eHgbvbgRP86mHB9-ifCRPAZ-Anhdn_R8qt1udiFv0NMni35w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2955326335</pqid></control><display><type>article</type><title>MRI‐based radiomic features for identifying recurrent prostate cancer after proton radiation therapy</title><source>DOAJ Directory of Open Access Journals</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><creator>Gumus, Kazim Z. ; Contreras, Samuel Serrano ; Al‐Toubat, Mohammed ; Harmon, Ira ; Hernandez, Mauricio ; Ozdemir, Savas ; Kumar, Sindhu ; Yuruk, Nurcan ; Mete, Mutlu ; Balaji, K. C. ; Bandyk, Mark ; Gopireddy, Dheeraj R.</creator><creatorcontrib>Gumus, Kazim Z. ; Contreras, Samuel Serrano ; Al‐Toubat, Mohammed ; Harmon, Ira ; Hernandez, Mauricio ; Ozdemir, Savas ; Kumar, Sindhu ; Yuruk, Nurcan ; Mete, Mutlu ; Balaji, K. C. ; Bandyk, Mark ; Gopireddy, Dheeraj R.</creatorcontrib><description>Purpose
Magnetic Resonance Imaging (MRI) evaluation of recurrent prostate cancer (PCa) following proton beam therapy is challenging due to radiation‐induced tissue changes. This study aimed to evaluate MRI‐based radiomic features so as to identify the recurrent PCa after proton therapy.
Methods
We retrospectively studied 12 patients with biochemical recurrence (BCR) following proton therapy. Two experienced radiologists identified prostate lesions from multi‐parametric MRI (mpMRI) images post‐proton therapy and marked control regions of interest (ROIs) on the contralateral side of the prostate gland. A total of 210 radiomic features were extracted from lesions and control regions on the T2‐weighted (T2WI) and Apparent Diffusion Coefficient (ADC) image series. Recursive Feature Elimination with Cross‐Validation method (RFE‐CV) was used for feature selection. A Multilayer Perceptron (MLP) neural network was developed to classify three classes: cancerous, benign, and healthy tissue. The 12‐core biopsy results were used as the gold standard for the segmentations. The classifier performance was measured using specificity, sensitivity, the area under receiver operating characteristic curve (AUC), and other statistical indicators.
Results
Based on biopsy results, 10 lesions were identified as PCa recurrence while eight lesions were confirmed to be benign. Ten radiomic features (10/210) were selected to build the multi‐class classifier. The radiomics classifier gave an accuracy of 0.83 in identifying cancerous, benign, and healthy tissue with a sensitivity of 0.80 and specificity of 0.85. The model yielded an AUC of 0.87, 95% CI [0.72–1.00] in differentiating cancer from the benign and healthy tissues.
Conclusions
Our proof‐of‐concept study demonstrates the potential of using radiomic features as part of the differential diagnosis of PCa on mpMRI following proton therapy. The results need to be validated in a larger cohort.</description><identifier>ISSN: 1526-9914</identifier><identifier>EISSN: 1526-9914</identifier><identifier>DOI: 10.1002/acm2.14293</identifier><identifier>PMID: 38409947</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>Biopsy ; Cancer ; Cancer therapies ; Care and treatment ; Diseases ; Feature selection ; Health aspects ; Magnetic resonance imaging ; Medical Imaging ; Medical imaging equipment ; Medical research ; Medicine, Experimental ; MRI ; Neural networks ; Patients ; Prostate cancer ; proton therapy ; Radiation therapy ; Radiomics ; Radiotherapy ; recurrence ; Relapse ; Support vector machines ; Tumors</subject><ispartof>Journal of Applied Clinical Medical Physics, 2024-03, Vol.25 (3), p.e14293-n/a</ispartof><rights>2024 The Authors. is published by Wiley Periodicals, Inc. on behalf of The American Association of Physicists in Medicine.</rights><rights>2024 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine.</rights><rights>COPYRIGHT 2024 John Wiley & Sons, Inc.</rights><rights>2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5163-58effabe1de6e5dd94ef30e7a7d43e834b68f7a52e113757aa698a956774b0593</citedby><cites>FETCH-LOGICAL-c5163-58effabe1de6e5dd94ef30e7a7d43e834b68f7a52e113757aa698a956774b0593</cites><orcidid>0000-0002-1450-6868</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10930012/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10930012/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,1419,11569,27931,27932,45581,45582,46059,46483,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38409947$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gumus, Kazim Z.</creatorcontrib><creatorcontrib>Contreras, Samuel Serrano</creatorcontrib><creatorcontrib>Al‐Toubat, Mohammed</creatorcontrib><creatorcontrib>Harmon, Ira</creatorcontrib><creatorcontrib>Hernandez, Mauricio</creatorcontrib><creatorcontrib>Ozdemir, Savas</creatorcontrib><creatorcontrib>Kumar, Sindhu</creatorcontrib><creatorcontrib>Yuruk, Nurcan</creatorcontrib><creatorcontrib>Mete, Mutlu</creatorcontrib><creatorcontrib>Balaji, K. C.</creatorcontrib><creatorcontrib>Bandyk, Mark</creatorcontrib><creatorcontrib>Gopireddy, Dheeraj R.</creatorcontrib><title>MRI‐based radiomic features for identifying recurrent prostate cancer after proton radiation therapy</title><title>Journal of Applied Clinical Medical Physics</title><addtitle>J Appl Clin Med Phys</addtitle><description>Purpose
Magnetic Resonance Imaging (MRI) evaluation of recurrent prostate cancer (PCa) following proton beam therapy is challenging due to radiation‐induced tissue changes. This study aimed to evaluate MRI‐based radiomic features so as to identify the recurrent PCa after proton therapy.
Methods
We retrospectively studied 12 patients with biochemical recurrence (BCR) following proton therapy. Two experienced radiologists identified prostate lesions from multi‐parametric MRI (mpMRI) images post‐proton therapy and marked control regions of interest (ROIs) on the contralateral side of the prostate gland. A total of 210 radiomic features were extracted from lesions and control regions on the T2‐weighted (T2WI) and Apparent Diffusion Coefficient (ADC) image series. Recursive Feature Elimination with Cross‐Validation method (RFE‐CV) was used for feature selection. A Multilayer Perceptron (MLP) neural network was developed to classify three classes: cancerous, benign, and healthy tissue. The 12‐core biopsy results were used as the gold standard for the segmentations. The classifier performance was measured using specificity, sensitivity, the area under receiver operating characteristic curve (AUC), and other statistical indicators.
Results
Based on biopsy results, 10 lesions were identified as PCa recurrence while eight lesions were confirmed to be benign. Ten radiomic features (10/210) were selected to build the multi‐class classifier. The radiomics classifier gave an accuracy of 0.83 in identifying cancerous, benign, and healthy tissue with a sensitivity of 0.80 and specificity of 0.85. The model yielded an AUC of 0.87, 95% CI [0.72–1.00] in differentiating cancer from the benign and healthy tissues.
Conclusions
Our proof‐of‐concept study demonstrates the potential of using radiomic features as part of the differential diagnosis of PCa on mpMRI following proton therapy. The results need to be validated in a larger cohort.</description><subject>Biopsy</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Diseases</subject><subject>Feature selection</subject><subject>Health aspects</subject><subject>Magnetic resonance imaging</subject><subject>Medical Imaging</subject><subject>Medical imaging equipment</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>MRI</subject><subject>Neural networks</subject><subject>Patients</subject><subject>Prostate cancer</subject><subject>proton therapy</subject><subject>Radiation therapy</subject><subject>Radiomics</subject><subject>Radiotherapy</subject><subject>recurrence</subject><subject>Relapse</subject><subject>Support vector machines</subject><subject>Tumors</subject><issn>1526-9914</issn><issn>1526-9914</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kd1qFDEUxwdRbK3e-AAy4I0Iu-ZzMrmSZfGj0CKIXoczmZNtyuxkzcxU9s5H6DP2STzbqaV6IYHk5OSX__kqipecLTlj4h34rVhyJax8VBxzLaqFtVw9fmAfFc-G4ZIxzmtZPy2OZK2YtcocF-H86-nNr-sGBmzLDG1M2-jLgDBOGYcypFzGFvsxhn3sN2VGP-VM93KX0zDCiKWH3mMuIYy0k3dM_a0QjJGs8QIz7PbPiycBugFf3J0nxfePH76tPy_Ovnw6Xa_OFl7zSi50jSFAg7zFCnXbWoVBMjRgWiWxlqqp6mBAC-RcGm0AKluD1ZUxqmHaypPi_ay7m5ottp4yzdC5XY5byHuXILq_X_p44TbpynFmJfVHkMKbO4Wcfkw4jG4bB49dBz2maXDUZaGkFLoi9PU_6GWack_1EaW1FJWUmqjlTG2gQxf7kCiwp9UitTr1GCL5V8ZWRiurDrJv5w-eWjxkDPfpc-YOA3eHgbvbgRP86mHB9-ifCRPAZ-Anhdn_R8qt1udiFv0NMni35w</recordid><startdate>202403</startdate><enddate>202403</enddate><creator>Gumus, Kazim Z.</creator><creator>Contreras, Samuel Serrano</creator><creator>Al‐Toubat, Mohammed</creator><creator>Harmon, Ira</creator><creator>Hernandez, Mauricio</creator><creator>Ozdemir, Savas</creator><creator>Kumar, Sindhu</creator><creator>Yuruk, Nurcan</creator><creator>Mete, Mutlu</creator><creator>Balaji, K. C.</creator><creator>Bandyk, Mark</creator><creator>Gopireddy, Dheeraj R.</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M2P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1450-6868</orcidid></search><sort><creationdate>202403</creationdate><title>MRI‐based radiomic features for identifying recurrent prostate cancer after proton radiation therapy</title><author>Gumus, Kazim Z. ; Contreras, Samuel Serrano ; Al‐Toubat, Mohammed ; Harmon, Ira ; Hernandez, Mauricio ; Ozdemir, Savas ; Kumar, Sindhu ; Yuruk, Nurcan ; Mete, Mutlu ; Balaji, K. C. ; Bandyk, Mark ; Gopireddy, Dheeraj R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5163-58effabe1de6e5dd94ef30e7a7d43e834b68f7a52e113757aa698a956774b0593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Biopsy</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Diseases</topic><topic>Feature selection</topic><topic>Health aspects</topic><topic>Magnetic resonance imaging</topic><topic>Medical Imaging</topic><topic>Medical imaging equipment</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>MRI</topic><topic>Neural networks</topic><topic>Patients</topic><topic>Prostate cancer</topic><topic>proton therapy</topic><topic>Radiation therapy</topic><topic>Radiomics</topic><topic>Radiotherapy</topic><topic>recurrence</topic><topic>Relapse</topic><topic>Support vector machines</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gumus, Kazim Z.</creatorcontrib><creatorcontrib>Contreras, Samuel Serrano</creatorcontrib><creatorcontrib>Al‐Toubat, Mohammed</creatorcontrib><creatorcontrib>Harmon, Ira</creatorcontrib><creatorcontrib>Hernandez, Mauricio</creatorcontrib><creatorcontrib>Ozdemir, Savas</creatorcontrib><creatorcontrib>Kumar, Sindhu</creatorcontrib><creatorcontrib>Yuruk, Nurcan</creatorcontrib><creatorcontrib>Mete, Mutlu</creatorcontrib><creatorcontrib>Balaji, K. C.</creatorcontrib><creatorcontrib>Bandyk, Mark</creatorcontrib><creatorcontrib>Gopireddy, Dheeraj R.</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Science Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Applied Clinical Medical Physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gumus, Kazim Z.</au><au>Contreras, Samuel Serrano</au><au>Al‐Toubat, Mohammed</au><au>Harmon, Ira</au><au>Hernandez, Mauricio</au><au>Ozdemir, Savas</au><au>Kumar, Sindhu</au><au>Yuruk, Nurcan</au><au>Mete, Mutlu</au><au>Balaji, K. C.</au><au>Bandyk, Mark</au><au>Gopireddy, Dheeraj R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MRI‐based radiomic features for identifying recurrent prostate cancer after proton radiation therapy</atitle><jtitle>Journal of Applied Clinical Medical Physics</jtitle><addtitle>J Appl Clin Med Phys</addtitle><date>2024-03</date><risdate>2024</risdate><volume>25</volume><issue>3</issue><spage>e14293</spage><epage>n/a</epage><pages>e14293-n/a</pages><issn>1526-9914</issn><eissn>1526-9914</eissn><abstract>Purpose
Magnetic Resonance Imaging (MRI) evaluation of recurrent prostate cancer (PCa) following proton beam therapy is challenging due to radiation‐induced tissue changes. This study aimed to evaluate MRI‐based radiomic features so as to identify the recurrent PCa after proton therapy.
Methods
We retrospectively studied 12 patients with biochemical recurrence (BCR) following proton therapy. Two experienced radiologists identified prostate lesions from multi‐parametric MRI (mpMRI) images post‐proton therapy and marked control regions of interest (ROIs) on the contralateral side of the prostate gland. A total of 210 radiomic features were extracted from lesions and control regions on the T2‐weighted (T2WI) and Apparent Diffusion Coefficient (ADC) image series. Recursive Feature Elimination with Cross‐Validation method (RFE‐CV) was used for feature selection. A Multilayer Perceptron (MLP) neural network was developed to classify three classes: cancerous, benign, and healthy tissue. The 12‐core biopsy results were used as the gold standard for the segmentations. The classifier performance was measured using specificity, sensitivity, the area under receiver operating characteristic curve (AUC), and other statistical indicators.
Results
Based on biopsy results, 10 lesions were identified as PCa recurrence while eight lesions were confirmed to be benign. Ten radiomic features (10/210) were selected to build the multi‐class classifier. The radiomics classifier gave an accuracy of 0.83 in identifying cancerous, benign, and healthy tissue with a sensitivity of 0.80 and specificity of 0.85. The model yielded an AUC of 0.87, 95% CI [0.72–1.00] in differentiating cancer from the benign and healthy tissues.
Conclusions
Our proof‐of‐concept study demonstrates the potential of using radiomic features as part of the differential diagnosis of PCa on mpMRI following proton therapy. The results need to be validated in a larger cohort.</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>38409947</pmid><doi>10.1002/acm2.14293</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-1450-6868</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1526-9914 |
ispartof | Journal of Applied Clinical Medical Physics, 2024-03, Vol.25 (3), p.e14293-n/a |
issn | 1526-9914 1526-9914 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10930012 |
source | DOAJ Directory of Open Access Journals; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); PubMed Central |
subjects | Biopsy Cancer Cancer therapies Care and treatment Diseases Feature selection Health aspects Magnetic resonance imaging Medical Imaging Medical imaging equipment Medical research Medicine, Experimental MRI Neural networks Patients Prostate cancer proton therapy Radiation therapy Radiomics Radiotherapy recurrence Relapse Support vector machines Tumors |
title | MRI‐based radiomic features for identifying recurrent prostate cancer after proton radiation therapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T11%3A57%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MRI%E2%80%90based%20radiomic%20features%20for%20identifying%20recurrent%20prostate%20cancer%20after%20proton%20radiation%20therapy&rft.jtitle=Journal%20of%20Applied%20Clinical%20Medical%20Physics&rft.au=Gumus,%20Kazim%20Z.&rft.date=2024-03&rft.volume=25&rft.issue=3&rft.spage=e14293&rft.epage=n/a&rft.pages=e14293-n/a&rft.issn=1526-9914&rft.eissn=1526-9914&rft_id=info:doi/10.1002/acm2.14293&rft_dat=%3Cgale_pubme%3EA796754946%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2955326335&rft_id=info:pmid/38409947&rft_galeid=A796754946&rfr_iscdi=true |